Windlas Biotech Ltd
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.[1]
- Market Cap ₹ 1,984 Cr.
- Current Price ₹ 961
- High / Low ₹ 1,182 / 697
- Stock P/E 29.8
- Book Value ₹ 275
- Dividend Yield 0.66 %
- ROCE 15.9 %
- ROE 12.2 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 19.7%
- Company's working capital requirements have reduced from 21.3 days to 14.4 days
Cons
- Company has a low return on equity of 12.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 274 | 315 | 352 | 307 | 329 | 428 | 466 | 513 | 631 | 760 | 904 | |
| Sales growth | +15% | -13% | +7% | +30% | +9% | +10% | +23% | +20% | +19% | ||
| 253 | 290 | 313 | 270 | 295 | 373 | 414 | 453 | 553 | 666 | 799 | |
| Operating Profit | 20 | 25 | 39 | 38 | 34 | 55 | 52 | 60 | 78 | 94 | 105 |
| OPM % | 7% | 8% | 11% | 12% | 10% | 13% | 11% | 12% | 12% | 12% | 12% |
| 1 | 4 | 4 | 54 | 2 | -19 | 7 | 10 | 13 | 18 | 18 | |
| Interest | 7 | 5 | 6 | 5 | 3 | 1 | 1 | 1 | 1 | 4 | 5 |
| Depreciation | 9 | 9 | 17 | 11 | 9 | 13 | 12 | 12 | 13 | 28 | 31 |
| Profit before tax | 6 | 14 | 20 | 76 | 25 | 22 | 46 | 57 | 77 | 80 | 87 |
| Tax % | 20% | 35% | 44% | 16% | 34% | 28% | 16% | 25% | 25% | 24% | 24% |
| 5 | 9 | 11 | 64 | 16 | 16 | 38 | 43 | 58 | 61 | 66 | |
| EPS in Rs | 2.50 | 5.04 | 6.15 | 35.05 | 8.90 | 8.69 | 17.48 | 20.04 | 27.98 | 29.10 | 31.49 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 20% | 20% | 20% | 20% | 20% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 21% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 17% |
| TTM: | 9% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 30% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 11 | 10 | 10 | 10 | 11 |
| Reserves | 132 | 141 | 119 | 187 | 203 | 193 | 384 | 392 | 440 | 495 | 570 |
| 53 | 62 | 57 | 32 | 29 | 32 | 7 | 5 | 4 | 33 | 35 | |
| 90 | 94 | 107 | 73 | 100 | 65 | 90 | 122 | 173 | 222 | 291 | |
| Total Liabilities | 281 | 304 | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
| 56 | 56 | 86 | 64 | 70 | 96 | 91 | 109 | 179 | 223 | 213 | |
| CWIP | 9 | 15 | 53 | 5 | 0 | 0 | 8 | 15 | 6 | 5 | 60 |
| Investments | 95 | 121 | 23 | 122 | 116 | 23 | 65 | 107 | 173 | 223 | 268 |
| 121 | 111 | 128 | 107 | 152 | 177 | 327 | 298 | 268 | 308 | 366 | |
| Total Assets | 281 | 304 | 290 | 298 | 338 | 296 | 491 | 529 | 626 | 760 | 907 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 47 | 7 | 35 | 19 | 25 | 11 | 9 | 61 | 109 | 68 | 105 | |
| -62 | -39 | -11 | -7 | -14 | -20 | -155 | -14 | -92 | -74 | -92 | |
| 38 | 5 | -26 | -6 | -5 | 1 | 130 | -44 | -15 | 1 | -13 | |
| Net Cash Flow | 24 | -27 | -2 | 6 | 5 | -8 | -15 | 3 | 2 | -5 | 0 |
| Free Cash Flow | 35 | -8 | 10 | 10 | 10 | 6 | -6 | -9 | 71 | 16 | 37 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 249% | 34% | 102% | 81% | 113% | 33% | 34% | 117% | 163% | 95% | 115% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2016 (S) | Mar 2017 (S) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 70 | 69 | 73 | 71 | 68 | 87 | 83 | 79 | 80 | 92 |
| Inventory Days | 49 | 62 | 54 | 36 | 85 | 55 | 71 | 84 | 57 | 63 | 40 |
| Days Payable | 137 | 120 | 130 | 110 | 143 | 53 | 76 | 98 | 121 | 129 | 156 |
| Cash Conversion Cycle | -14 | 13 | -7 | -1 | 13 | 70 | 81 | 69 | 15 | 14 | -24 |
| Working Capital Days | -46 | -37 | -30 | -12 | 2 | 40 | 85 | 71 | 32 | 17 | 14 |
| ROCE % | 10% | 15% | 12% | 19% | 15% | 14% | 18% | 17% | 16% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| CDMO Number of Customers Catered count |
|
|||||||
| CDMO Number of Products Catered count |
||||||||
| Complex Generic Variations count |
||||||||
| Installed Capacity - Tablets & Capsules Mn units per annum |
||||||||
| Stockists and Distributors count |
||||||||
| Top 10 Customer Concentration % of CDMO revenue |
||||||||
| Trade Generics Number of Brands count |
||||||||
| Capacity Utilization % |
||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Q2 & H1 FY27 Earnings Conference Call Transcript
-
Recording Of Conference Call
- Audio recording of October 30, 2026 analyst call for Q2 and H1 FY26 uploaded on website.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Windlas Biotech reported H1/Q2 FY27 results, crossed Rs.500 crore revenue, commercialized Plant-6, and secured EU GMP certification.
-
Announcement under Regulation 30 (LODR)-Change in Management
- Approved Q2/H1 FY27 results; Ashok Kumar Windlass resigned as WTD/director, Hitesh Windlass appointed chairman on Nov 5, 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
- Q2/H1 FY27 results approved; Ashok Kumar Windlass resigned as WTD; Hitesh Windlass appointed Chairman.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2022
from nse
Concalls
-
Nov 2026Transcript PPT REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Sep 2021PPT
Market Position
Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations, contract development, and manufacturing organization (CDMO) industry in India, in terms of revenues. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics. [1]